JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oka, S.
Right arrow Articles by Ito, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oka, S.
Right arrow Articles by Ito, O.
Journal of Nuclear Medicine Vol. 48 No. 1 46-55
© 2007 by Society of Nuclear Medicine


Basic Science Investigation

A Preliminary Study of Anti-1-Amino-3-18F-Fluorocyclobutyl-1-Carboxylic Acid for the Detection of Prostate Cancer

Shuntaro Oka1, Ryota Hattori1, Fumie Kurosaki1, Masahito Toyama1, Larry A. Williams2, Weiping Yu2, John R. Votaw2, Yasunori Yoshida1, Mark M. Goodman2 and Osamu Ito1

1 Research Center, Nihon Medi-Physics Co., Ltd., Sodegaura, Chiba, Japan; and 2 PET Center and Department of Radiology, Emory University, Atlanta, Georgia

Correspondence: For correspondence or reprints contact: Shuntaro Oka, PhD, DVM, Research Center, Nihon Medi-Physics Co., Ltd., Kitasode 3-1, Sodegaura Chiba 299-0266, Japan. E-mail: shuntaro_oka{at}nmp.co.jp

We evaluated the feasibility of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid (anti-18F-FACBC) in diagnosing prostate cancer (PCa), using a rat orthotopic prostate cancer transplantation (OPCT) model. Furthermore, using in vivo experiments, we examined the potential of anti-18F-FACBC for differentiating between PCa and inflammation and between PCa and benign prostatic hyperplasia (BPH). Methods: The OPCT model was developed by transplanting DU145, a human PCa cell line, into the ventral prostate of athymic F344 rats. To develop a dual PCa and inflammation (DPCI) model, MAT-Ly-Lu-B2—a rat PCa cell line—was transplanted subcutaneously into male Copenhagen rats. Streptozotocin was injected into the hind footpad of these rats for inducing popliteal lymphadenitis. For inducing the BPH, normal F344 rats were castrated and injected subcutaneously with testosterone propionate. In biodistribution studies, the rats were injected with anti-18F-FACBC or 18F-FDG and sacrificed at 15 or 60 min after injection. We performed dynamic small-animal PET of the abdominal portion of the OPCT rats for 60 min after the injection of anti-18F-FACBC or 18F-FDG. Results: The biodistribution in the OPCT rats at 60 min after injection showed that the uptake of anti-18F-FACBC and 18F-FDG into the PCa tissue was 1.58 ± 0.40 %ID/cm3 (percentage injected dose per cm3) and 1.48 ± 0.90 %ID/cm3, respectively (P > 0.05). The accumulation of anti-18F-FACBC in the urinary bladder at 60 min after injection was 3.09 ± 1.43 %ID/cm3, whereas that of 18F-FDG was 69.31 ± 16.55 %ID/cm3 (P < 0.05). Consequently, small-animal imaging with anti-18F-FACBC facilitated the visualization of the PCa tissue of the OPCT rats with higher contrast than 18F-FDG. Furthermore, in comparison with 18F-FDG, apparently higher ratios of PCa to inflammation and PCa to BPH accumulation of anti-18F-FACBC were demonstrated in the animal models. Conclusion: FACBC PET is believed to be useful not only for the visualization of human PCa but also for differentiating between PCa and inflammation and between PCa and BHP.

Key Words: anti-18F-FACBC • 18F-FDG • prostate cancer • small-animal imaging

COPYRIGHT © 2006 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2007 by the Society of Nuclear Medicine.